Critical Care Obstetrics and Gynecology

The selective effect of NSC-631570 on women reproductive cancers

European Congress on Vaccines & Vaccination and Gynecologic Oncology
October 26 -27, 2018 Budapest , Hungary

Wassil Nowicky

Nowicky Pharma/ Ukrainian Anti-Cancer Institute, Austria

ScientificTracks Abstracts: Crit Care Obst & Gyne

DOI: 10.21767/2471-9803-C1-002

Abstract

First indications on the selective effect of NSCâ�?631570 on the cancer cells were provided in an early study when different oxygen consumption by normal liver cells and Ehrlich’s tumor ascitic cells after the incubation with NSCâ�?631570 was re-vealed. In the tests on the Jurkat lympho-ma model, NSCâ�?631570 has been proven to be a strong apoptosis inductor. Profound research showed NSCâ�?631570 brought about the depolarization of mitochondrial membranes and consequently the activation of caspases. NSCâ�?631570 induced apoptosis in a panel of cancer cell lines (ovarial and cervical cancer HeLa, HeKB, HeKS32, HeBcl3, HeNFR and HeIKK, human colon cancer SW480, human renal carcinoma HEK293, human osteosarcoma MGâ�?63) by activating the caspases of the intrinsic cell death pathway. Interestingly, nonâ�?transformed fibroblasts (hTERT) cell line was insensitive to the drug. In the tests on human ovarian and cervix carcinoma cells HeLa, squamous carcinoma cells WHCO5, normal kidney cell line Graham 293, and transformed kidney cell line Vero from African green monkey, NSCâ�?631570 inhibited the tubulin polymerisation and caused a metaphase block in cancer cells which is characterized by abnormal chromosomal distribution, and results in the formation of micronuclei and in apoptosis.

Biography

Wassil Nowicky (Dipl Ing, Dr techn, DDD rh c) is the Director of Nowicky Pharma and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). He has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) with the end of 1955, with graduation to “Diplomingeniueur” in 1960 which title was nostrificated in Austria in 1975. He became the very first Scientist in the development of the anticancer protonic therapy and is the Inventor of NSC-631570, the anticancer preparation on basis of celandine alkaloids. He used the factor that cancer cells are more negatively charged than normal cells and invented the celandine alkaloid with a positive charge, thanks to which it accumulates in cancer cells very fast. He is the Author of over 300 scientific articles dedicated to cancer research. He is a real Member of the New York Academy of Sciences, Member of the European Union for applied immunology and of the American Association for scientific progress, honorary Doctor of the Yanka Kupala State University of Grodno, Doctor Honoris Causa of the Open International University for Complementary Medicine in Colombo, Honorary Member of the Austrian Society on the Name of Albert Schweizer. He has received merits of National Guild of the award of Austrian Society of sanitary, hygiene and public health services and others.

E-mail: dr.nowicky@yahoo.de